牛牛AI助理已提取核心訊息
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has been granted an additional 180-day period to meet Nasdaq's minimum bid price requirement. The company's common stock, trading under the symbol SNTI, was initially notified of non-compliance with the $1.00 minimum bid price rule after closing below this threshold for 30 consecutive business days. The initial 180-day grace period ended on February 5, 2024, without achieving compliance. Consequently, Senti Biosciences applied for and was approved to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market, effective January 25, 2024. This transfer allows the company to benefit from a second 180-day grace period, which extends until August 5, 2024, to regain compliance. During this period, the company must maintain a closing bid price...Show More
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has been granted an additional 180-day period to meet Nasdaq's minimum bid price requirement. The company's common stock, trading under the symbol SNTI, was initially notified of non-compliance with the $1.00 minimum bid price rule after closing below this threshold for 30 consecutive business days. The initial 180-day grace period ended on February 5, 2024, without achieving compliance. Consequently, Senti Biosciences applied for and was approved to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market, effective January 25, 2024. This transfer allows the company to benefit from a second 180-day grace period, which extends until August 5, 2024, to regain compliance. During this period, the company must maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. Senti Biosciences has indicated that it may consider a reverse stock split as a potential remedy to address the bid price deficiency if necessary. The company cautions that there is no assurance of regaining compliance within the second grace period, and failure to do so may result in delisting. The company's CEO, Timothy Lu, M.D., Ph.D., signed the report dated February 6, 2024.
特拉華州註冊成立的生物技術公司Senti Biosciences, Inc. 已獲准再延長180天以滿足納斯達克的最低出價要求。該公司的普通股交易代碼爲SNTI，在連續30個工作日收盤低於該門檻後，最初被告知未遵守1.00美元的最低出價規則。最初的 180 天寬限期於 2024 年 2 月 5 日結束，但沒有達到合規要求。因此，Senti Biosciences申請並獲准將其上市從納斯達克全球市場轉移到納斯達克資本市場，自2024年1月25日起生效。此次轉讓使公司能夠享受第二個180天的寬限期，該寬限期延長至2024年8月5日，以恢復合規。在此期間，公司必須至少連續10個工作日將收盤價維持在至...展開全部
特拉華州註冊成立的生物技術公司Senti Biosciences, Inc. 已獲准再延長180天以滿足納斯達克的最低出價要求。該公司的普通股交易代碼爲SNTI，在連續30個工作日收盤低於該門檻後，最初被告知未遵守1.00美元的最低出價規則。最初的 180 天寬限期於 2024 年 2 月 5 日結束，但沒有達到合規要求。因此，Senti Biosciences申請並獲准將其上市從納斯達克全球市場轉移到納斯達克資本市場，自2024年1月25日起生效。此次轉讓使公司能夠享受第二個180天的寬限期，該寬限期延長至2024年8月5日，以恢復合規。在此期間，公司必須至少連續10個工作日將收盤價維持在至少1.00美元。Senti Biosciences表示，如有必要，它可能會考慮將反向股票拆分作爲解決出價缺陷的潛在補救措施。該公司警告說，無法保證在第二個寬限期內恢復合規，不這樣做可能會導致退市。該公司首席執行官、醫學博士、博士蒂莫西·盧簽署了2024年2月6日的報告。
有用
沒用